Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period

Expert Opinion on Biological Therapy

Volumn 14, Issue 1, 2014, Pages 51-61

  Tran, Diane H D ^a   Wong, Gordon T C ^a   Chee, Yee Eot ^a   Irwin, Michael G ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Blood transfusion; Erythropoiesis; Erythropoietin; Perioperative; Surgery

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ANGINA PECTORIS; ARTERY THROMBOSIS; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ERYTHROPOIESIS; HEART INFARCTION; HEART SURGERY; HEMATOCRIT; HOSPITALIZATION; HUMAN; HYPERTENSION; IRON DEFICIENCY; IRON STORAGE; MULTIPLE DRUG DOSE; OPERATIVE BLOOD LOSS; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PHLEBITIS; PLATELET REACTIVITY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROTEIN EXPRESSION; QUALITY OF LIFE; RETICULOCYTE COUNT; REVIEW; SINGLE DRUG DOSE; SPINE SURGERY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION;

ANEMIA; ANIMALS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HUMANS; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890146894     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.858116     Document Type: Review

References (50)

1. Meybohm P, Zacharowski K. Preoperative anaemia and postoperative outcomes in non-cardiac surgery. Lancet 2011;378:1396
2. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113:3406-17
3. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108:759-69
4. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003;31(12):S687-97
5. Munoz M, Garcia-Erce JA, Villar I, Thomas D. Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations. Vox Sang 2009;96:1-13
6. Fullerton DA, Campbell DN, Whitman GJ. Use of human recombinant erythropoietin to correct severe preoperative anemia. Ann Thorac Surg 1991;51:825-6
7. Goodnough LT, Maniatis A, Earnshaw P. Detection, evaluation and management of preoperative anaemia in the elective orthopaedic patient: NATA guidelines. BJA 2011;106:13-22
8. Weiss G, Goodnough LT. Anemia of chronic disease. NEJM 2005;352(10):1011-23
9. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J 2003;79:367-76
10. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg 2013;116:15-34
11. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997;336:933-8
12. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95(9):2983-9
13. NICE Guidelines. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia. Reviewed 2009
14. Macdougall IC. Novel erythropoiesisstimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3(1):200-7
15. Qureshi M, Momoh I, Bankes M, et al. Erythropoietin provides a useful strategy for treating preoperative anemia in planned elective orthopedic surgery: an analysis of benefit in routine practice. Transfusion 2012;52:2063-4
16. Marcucci C, Madjdpour C, Spahn DR. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 2004;70:15-28
17. Goodnough LT, Monk TG. Erythropoietin therapy in the perioperative setting. Clin Orthop Relat Res 1998;82-8
18. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. NEJM 2007;357:965-76
19. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction. JAMA 2011;305:1863-72
20. Crosby E. Perioperative use of erythropoietin. Am J Ther 2002;9:371-6
21. Kiyama H, Ohshima N, Imazeki T, Yamada T. Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg 1999;68:1652-6
22. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996;36:29-36
23. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop (Belle Mead NJ) 1996;25:544-52
24. Yoo YC, Shim JK, Kim JC, et al. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011;115:929-37
25. Na HS, Shin SY, Hwang JY, et al. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011;51:118-24
26. Weber EW, Slappendel R, Hemon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005;22:249-57
27. Wurnig C, Schatz K, Noske H, et al. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients schedules for elective surgery not eligible for autologous blood donation. Eur Surg Res 2001;33:303-10
28. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000;133:845-54
29. Heiss MM, Tarabichi A, Delanoff C, et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery 1996;119:523-7
30. Kettelhack C, Hones C, Messinger D, Schlag PM. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998;85:63-7
31. Qvist N, Boesby S, Wolff B, Hansen CP. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery - prospective double-blind placebo-controlled study. World J Surg 1999;23:30-5
32. Kosmadakis N, Messaris E, Maris A, et al. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003;237:417-21
33. Christodoulakis M, Tsiftsis DD. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study. Ann Surg Oncol 2005;12:718-25
34. Study Group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Canadian Orthopedic Perioperative Erythropoietin. Lancet 1993;341:1227-32
35. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 1996;78:62-72
36. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 1997;89:411-18
37. Eidemak I, Friedberg MO, Ladefoged SD, et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1992;7:526-9
38. Horl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. Acta Haematol 1992;87(Suppl 1):16-19
39. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion 2012;52:1584-92
40. Aderinto J, Brenkel IJ. Pre-operative predictors of the requirement for blood transfusion following total hip replacement. J Bone Joint Surg Br 2004;86:970-3
41. Bacuzzi A, Dionigi G, Piffaretti G, et al. Preoperative methods to improve erythropoiesis. Transplant Proc 2011;43:324-6
42. Piagnerelli M, Vincent J-L. The use of erythropoiesis-stimulating agents in the intensive care. Crit Care Clin 2012;28:345-62
43. Weltert L, D'Alessandro S, Nardella S, et al. Preoperative very short-term, highdose erythropoietin administration diminishes blood transfusion rate in offpump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010;139:621-6; discussion 6-7
44. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-9
45. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90
46. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
47. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
48. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 2010;362:189-92
49. Stowell CP, Jones SC, Enny C, et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976) 2009;34:2479-85
50. Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe. Br J Anaesth 2012;109:55-68